𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cholesterol-lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis

✍ Scribed by Renée E. Poupon; Khadija Ouguerram; Yves Chrétien; Claudine Verneau; Eveline Eschwège; Thierry Magot; Raoul Poupon


Publisher
John Wiley and Sons
Year
1993
Tongue
English
Weight
591 KB
Volume
17
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

✦ Synopsis


We have previously shown in a 2-yr controlled trial that hypercholesterolemia, frequent in primary biliary cirrhosis, is lowered by ursodeoxycholic acid (13 to 15 mg daily). To further investigate this effect, we analyzed the influence of long-term ursodeoxycholic acid administration on serum lipids, lipoproteins and bile acids. The study involved a subgroup of 33 noncirrhotic patients (17 received ursodeoxycholic acid and 16 received a placebo) analyzed at inclusion and after 2 yr. The total serum cholesterol concentration was markedly reduced in the ursodeoxycholic acid-treated patients in comparison with the controls (mean rt- S.E.M. = 7.49 2 0.42 mmol/L and 7.07 rt-0.23 mmol/L at entry and 4.44 +-0.40 mmoln and 6.89 rt-0.27 mmol/L at 2 yr in the ursodeoxycholic acid and placebo groups, respectively; p < 0.02). Quantitatively, this decrease was mainly caused by a fall in low-density-lipoprotein cholesterol, but very low density-lipoprotein cholesterol levels also fell significantly. High-densitylipoprotein cholesterol levels remained stable in both groups, but the high-density-1ipoproteinJhigh-density-lipoprotein, cholesterol ratio fell significantly during ursodeoxycholic acid treatment. No significant change occurred in total triglyceride or total phospholipid levels. In the treated group, the proportion of ursodeoxycholic acid increased (up to 60% of total circulating bile acids), whereas that of cholic and chenodeoxycholic acids fell significantly. In conclusion, the cholesterol-lowering effect of ursodeoxycholic acid could be related to an improvement of cholestasis, modifications in cholesterol metabolism or both. Changes in endogenous bile acid composition induced by ursodeoxycholic acid might be the common denominator of these two mechanisms. (HEPATOLOGY 1993; 17577-582.) As in other chronic cholestatic diseases, the serum cholesterol concentration is frequently elevated in PBC


📜 SIMILAR VOLUMES


Biliary bile acids in primary biliary ci
✍ Burton Combes; Robert L. Carithers Jr.; Willis C. Maddrey; Santiago Munoz; Guada 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB 👁 1 views

Bile acid composition in fasting duodenal bile was assessed at entry and at 2 years in patients with primary biliary cirrhosis (PBC) enrolled in a randomized, doubleblind, placebo-controlled trial of ursodeoxycholic acid (UDCA) (10-12 mg/kg/d) taken as a single bedtime dose. Specimens were analyzed

Ursodeoxycholic acid inhibits eosinophil
✍ Kiyoshi Yamazaki; Kazuyuki Suzuki; Atsushi Nakamura; Shunichi Sato; Keith D. Lin 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 421 KB 👁 1 views

Eosinophilia is a distinctive feature of primary biliary cirrhosis (PBC), especially in its early stages. Intriguingly, treatment with ursodeoxycholic acid (UDCA) ameliorates eosinophilia as well as liver tests in patients with PBC. It remains unknown, however, whether eosinophils in PBC patients ar

Effect of ursodeoxycholic acid on bile a
✍ Dr. Ashok K. Batta; Gerald Salen; Renu Arora; Sarah Shefer; G. Stephen Tint; Joh 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 571 KB

We have compared the effect of ursodeoxycholic acid with placebo on the clinical state, blood liver chemistries and serum and urinary bile acids in four patients with primary biliary cirrhosis. All parameters were evaluated monthly, and bile acid composition was measured by capillary gas-liquid chro